Beta-cell response to metformin-glibenclamide combination tablets (Glucovance®) in patients with type 2 diabetes

International Journal of Clinical Practice

Volumn 60, Issue 7, 2006, Pages 783-790

  Bruce, S ^a   Park, J S ^a   Fiedorek, F T ^a   Howlett, Harry C S ^b,c  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^b Merck Sante   (France)

^c Merck Sharp & Dohme Limited   (United Kingdom)

Author keywords

cell function; Glibenclamide; Glyburide; Metformin; Oral antidiabetic agents; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET RESTRICTION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GLUCOSE TOLERANCE TEST; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; METFORMIN; MIDDLE AGED; TABLETS; TREATMENT OUTCOME;

EID: 33745104416     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.00994.x     Document Type: Article

References (31)

1. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-68.
2. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes ? Diabetes 2002; 51 (Suppl. 1): S117-21.
3. Defronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995; 333: 541-9.
4. Schernthaner G, Matthews DR, Charbonnel B et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004; 89: 6068-76.
5. Garber AJ, Larsen J, Schneider SH et al. Simultaneous glyburide/ metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002; 4: 201-8.
6. Garber A, Donovan D, Dandona P et al. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3598 -604.
7. Garber AJ, Bruce S, Fiedorek FT. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: An open-label extension study. Clin Ther 2002; 24: 1401-13.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837 -53.
9. Ferrannini E, Del Prato S, DeFronzo R. Glucose kinetics. Tracer methods. In: Clarke W, Larner J, Pohl S, eds. Methods in Diabetes Research, Chichester, UK: Wiley, 1986; pp. 107-141.
10. Steele R. Influence of glucose loading and of injected insulin on the hepatic glucose output. Ann N Y Acad Sci 1959; 82: 420-30.
11. Radziuk J, Norwich K, Vranic M. Experimental validation of measurements of glucose turnover in nonsteady state. Am J Physiol 1978; 234: E84-93.
12. Radziuk J, Norwich K, Vranic M. Measurement and validation of nonsteady turnover rates with applications to the insulin and glucose systems. Fed Proc 1974; 33: 1855-64.
13. Mokan M, Gerich J. A simple insulin infusion algorithm for establishing and maintaining overnight near-normoglycemia in type I and type II diabetes. J Clin Endocrinol Metab 1992; 74: 943-5.
14. De Fronzo R, Tobin J, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-23.
15. Elahi D. In praise of the hyperglycemic clamp. A method for assessment of beta-cell sensitivity and insulin resistance. Diabetes Care 1996 19: 278-86.
16. Mitrakou A, Vuorinen-Markkola H, Raptis G et al. Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemia clamp. J Clin Endocrinol Metab 1992; 75: 379-82.
17. Marathe PH, Arnold ME, Meeker J, Greene DS, Barbhaiya RH. Pharmacokinetics and bioavailability of a metformin/glyburide combination tablet administered alone and with food. J Clin Pharmacol 2000; 40: 1494-502.
18. Hosker JP, Rudenski AS, Burnett MA et al. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 1989; 38: 767-72.
19. Blonde L, Rosenstock J, Mooradian AD et al. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab 2002; 4: 368-75.
20. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance ®) in type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002; 19: 673-80.
21. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992; 13: 415-31.
22. Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes -a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002; 143: 339-42.
23. Kahn SE, Montgomery B, Howell W et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001; 86: 5824-9.
24. Donahue SR, Turner KC, Patel S. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes. Clin Pharmacokinet 2002; 41: 1301-9.
25. Carlson RF, Isley WL, Ogrinc FG, Klobucar TR. Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin-dependent diabetes mellitus: A multicenter, double-blind, randomized trial. Clin Ther 1993; 15: 788-96.
26. Scheen AJ, Jaminet C, Luyckx AS, Lefebvre PJ. Pharmacokinetics and pharmacological properties of two galenical preparations of glibenclamide, HB419 and HB420, in non insulin-dependent (type 2) diabetes. Int J Clin Pharmacol Ther Toxicol 1987; 25: 70-6.
27. Howlett H, Porte F, Allavoine T et al. The development of an oral antidiabetic combination tablet: Design, evaluation and clinical benefits for patients with type 2 diabetes. Curr Med Res Opin 2003; 19: 218-25.
28. Breda E, Cavaghan MK, Toffolo G et al. Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity. Diabetes 2001; 50: 150-8.
29. Kosaka K, Kuzuya T, Akanuma Y et al. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980; 18: 23-8.
30. Palaniappan LP, Carnethon MR, Fortmann SP. Heterogeneity in the relationship between ethnicity, BMI, and fasting insulin. Diabetes Care 2002; 25: 1351-7.
31. Davidson JA, Scheen AJ, Howlett HC. Tolerability profile of metformin/ glibenclamide combination tablets (Glucovance): A new treatment for the management of type 2 diabetes mellitus. Drug Saf 2004; 27: 1205-16.